公开(公告)号：US20100183630A1

公开(公告)日：2010-07-22

申请号：US11922881

申请日：2006-06-29

申请人： Marcelo Filgueira ,  Daniel Chelsky ,  Joel Lanoix ,  Kevin Eng ,  Pierre Thibault ,  Denis Faubert ,  Navdeep Jaitly ,  Sylvain Brunet ,  Frank R.M. Aguilera ,  John S.-C. Tsang ,  Michael Hu ,  Joachim B. Ostermann ,  Marguerite Boulos ,  Paul E. Kearney ,  Heather Butler ,  Sajani Swamy ,  Lyes Hamaidi

发明人： Marcelo Filgueira ,  Daniel Chelsky ,  Joel Lanoix ,  Kevin Eng ,  Pierre Thibault ,  Denis Faubert ,  Navdeep Jaitly ,  Sylvain Brunet ,  Frank R.M. Aguilera ,  John S.-C. Tsang ,  Michael Hu ,  Joachim B. Ostermann ,  Marguerite Boulos ,  Paul E. Kearney ,  Heather Butler ,  Sajani Swamy ,  Lyes Hamaidi

IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  G01N33/574 ,  A61P35/04

CPC分类号： G01N33/57419 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/4748 ,  G01N2500/04

摘要： Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-005蛋白的表达与癌症相关，并且过度表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-005与异常发育和生长相关，并且可用作鉴定抗癌药物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-005表达或活性的化合物的方法，包括：使候选化合物与TAT-005接触并检测所述化合物与所述TAT-005之间是否存在结合，或 检测TAT-005表达或活性的变化。 还包括用于鉴定调节TAT-005表达或活性的化合物的方法，包括：向细胞或细胞群体施用化合物，并检测TAT-005表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070106065A1

公开(公告)日：2007-05-10

申请号：US11344933

申请日：2006-01-31

申请人： Paul Kearney ,  Heather Butler ,  Navdeep Jaitly ,  Sajani Swamy ,  Lyes Hamaidi ,  Marcelo Filgueira ,  Pierre Thibault ,  Denis Faubert ,  Daniel Chelsky ,  Joel Lanoix ,  Sylvain Brunet ,  Kevin Eng ,  Frank Aguilera ,  John Tsang ,  Michael Hu ,  Joachim Ostermann ,  Marguerite Boulos

发明人： Paul Kearney ,  Heather Butler ,  Navdeep Jaitly ,  Sajani Swamy ,  Lyes Hamaidi ,  Marcelo Filgueira ,  Pierre Thibault ,  Denis Faubert ,  Daniel Chelsky ,  Joel Lanoix ,  Sylvain Brunet ,  Kevin Eng ,  Frank Aguilera ,  John Tsang ,  Michael Hu ,  Joachim Ostermann ,  Marguerite Boulos

IPC分类号： C07K14/82 ,  C07K16/30 ,  C12P21/06 ,  A61K39/395 ,  A61K39/00 ,  C12P21/08 ,  C12P21/04

CPC分类号： C07K14/82 ,  C07K14/4748 ,  C07K16/3046

摘要： Surprisingly, the present inventors have discovered that expression of TAT-001 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-001 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-001 expression or activity, comprising: contacting a candidate compound with a TAT-001 and detecting the presence or absence of binding between said compound and said TAT-001, or detecting a change in TAT-001 expression or activity. Methods are also included for the identification of anti-cancer compounds and compounds that modulate TAT-001 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-001 expression or activity.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-001蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-001与异常发育和生长有关，可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-001表达或活性的化合物的方法，包括：使候选化合物与TAT-001接触并检测所述化合物与所述TAT-001之间是否存在结合，或 检测TAT-001表达或活性的变化。 还包括用于鉴定调节TAT-001表达或活性的抗癌化合物和化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-001表达或活性的变化。